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Oxidative stress markers are associated with both depression and smoking.
Increased nitric oxide and ﬁbrinogen levels are seen in smokers and depression.
There is a correlation between depressed smokers and lipid hydroperoxides.
Depressed smokers have an elevated disability for work.
Depressed smokers have a higher severity of depression and more suicide attempts.
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a b s t r a c t
To determine if oxidative stress and inﬂammation are linked with major depressive disorder, nicotine
dependenceandbothdisorders combined. This study comprised150 smokers and191never smokers. The
instrumentswere: a socio-demographic questionnaire, diagnoses ofmood disorder and nicotine depend-
ence according to DSM-IV, (SCID-IV), and the Alcohol, Smoking and Substance Involvement Screening
Test. Laboratory assessments included: nitric oxide metabolites (NOx), lipid hydroperoxides, malondi-
aldehyde (MDA), total reactiveantioxidantpotential (TRAP), advancedoxidationproteinproducts (AOPP),
ﬁbrinogen concentrations, homocysteine, erythrocytes sedimentation rate (ESR) and high-sensitivity C-
reactive protein (hs-CRP) were assayed from blood specimens. Statistically signiﬁcant differences were
found among depressed smokers who had more severe depressive symptoms, a higher risk of alcohol
consumption, more suicide attempts, and more disability for work than non-depressed never smokers.
Depressed smokers had signiﬁcantly higher levels of NOx, ﬁbrinogen, hs-CRP, AOPP, ESR and lower levels
of TRAP compared to non-depressed never smokers. Depressed smokers had signiﬁcant levels of oxida-
tive stress and inﬂammatory biomarkers after adjusting for gender, age, years of education, disability for
work, and laboratory measures. The levels of NOx, lipid hydroperoxides, AOPP, and ﬁbrinogen were sub-
stantially higher, whereas levels of TRAP were lower in depressed smokers compared to non-depressed
never smokers. (1) Depressed smokers exhibited altered concentrations of NOx, lipid hydroperoxides,
AOPP, TRAP, and ﬁbrinogen. (2) Depressed smokers were more unable to work, showed more severe
depressive symptoms and attempted suicide more frequently.
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. Introduction
Tobacco use is a risk factor for disability and morbidity, as well
s the most preventable cause of death in the world [32]. Smokers
ore often presented with impaired work/domestic functionality,
ore frequent hospitalization, more depressive disorders, more
edative use and a family history of mental disorders, as well as
coring lower on the quality of life scale compared with never
mokers [6]. Smoking with nicotine dependence increases the risk
f developing major depressive disorders [25], contributes to more
evere depressive symptoms [3,14] and is associated with suicidal
ehavior [4,20].
Major depressive disorder is accompanied by an increase in
xidative stress and a decrease in antioxidant status, which dam-
ges neurons and has an important role in the pathophysiology
f depressive disorders [2,10,17,19,22]. There is also data link-
ng oxidative stress and nicotine dependence [28]. Oxidative and
itrosative stress and inﬂammation induced damage to fatty acids,
roteins, DNA, mitochondria and consequent autoimmune reac-
ions, which link to neuroprogression and degenerative processes
hat occur in depressive disorders [2,19]. Nitric oxide plasma con-
entration is associatedwith cognitive impairment in patientswith
ecurrent depressive disorders [29]. These alterations may lead
rain damage, which may be a pathway to neurodegenerative dis-
ases [13], as well as neuroprogression of mood disorders [2,19].
The purpose of this study was to elucidate the involvement
f oxidative and nitrosative stress and inﬂammatory markers,
ncluding nitric oxide metabolites (NOx), lipid hydroperoxides,
alondialdehyde (MDA), advanced oxidation protein products
AOPP), total reactive antioxidant potential (TRAP) and inﬂam-
atory biomarkers (high-sensitivity C-reactive protein (hs-CRP),
brinogen, homocysteine, erythrocytes sedimentation rate (ESR))
n depressed and non-depressed smokers compared to depressed
nd non-depressed never smokers. We also hypothesized that
epressive smokers would have co-occurring disorders such as
ore risk of alcohol use, more suicide attempts, more physical dis-
ases, more severe symptoms, as well as more disability for work
han non-depressed never smokers.
. Materials and methods
.1. Study population
Smokers (n=150) were recruited from outpatients at the Cen-
re of Approach and Treatment for Smokers, at Londrina State
niversity (UEL), Paraná, Brazil and never smokers (n=191) were
ecruited fromstaff ofUEL. The sample size calculationofwasbased
n smokers and never smokers with and without depression. The
tudy sample size calculation showed that a sample of 34 never
mokers and 27 smokers (total n=61) would be able to detect a
9% prevalence of depressive disorders among smokers compared
o 17%depressive disorders amongnon-smokers (odds ratio =7.03)
ith a conﬁdence level of 0.95 and 95% power. It was assumed
hat the ratio of control to case was 1.27. However we are able to
ecruit 191 never smokers and 150 smokers and that sample size
ould be adequately powered to detect population level preva-
ence of depressive disorders among smokers and never smokers
s reported in the literature [6,7].
Smokers and never smokers were men and women aged 18–60
nd all ethnicities were accepted for this study. The study was con-
ucted from March 2011 to July 2012.Exclusion criteria were presence of medical comorbidities
ncluding chronic obstructive pulmonary disease, rheumatoid
rthritis, systemic lupus erythematosus, inﬂammatory bowel dis-
ase, HIV infection, neurodegenerative and neuroinﬂammatoryetters 544 (2013) 136–140 137
disorders, such as Alzheimer’s, Huntington’s and Parkinson’s disor-
der, multiple sclerosis and stroke, conditions such as hemodialysis,
use of interferon. All these conditions are known to share periph-
eral inﬂammation and cell-mediated immune activation [17]. All
study participants needed to have normal blood values on the fol-
lowing laboratory tests: hemogram, aspartate transaminase (AST),
alanine transaminase (ALT), urea, and creatinine.
All subjects had givenwritten informed consent to participate in
the study after the approval of this research by the Ethics Research
Committee at Londrina State University (UEL), number 250/2010.
2.2. Instruments
2.2.1. Questionnaire
A self-reported questionnaire was used to gather information
on socio-demographic, clinical characteristics and smoking status.
2.2.2. Major depressive disorder and nicotine dependence
The diagnoses of major depressive disorder and nicotine
dependence were made at interview by a trained clinician using
DSM-IV, criteria translated and validated into Portuguese [8].
2.2.3. Hamilton Depression Rating Scale
A translated and validated version of the Hamilton Depres-
sion Rating Scale, adapted to the Brazilian cultural context and
Portuguese language [21] was used to measure the severity of
depression in study participants who had been diagnosed with
major depressive disorder.
2.2.4. The Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST)
The World Health Organization (WHO) developed Alcohol,
Smoking and Substance Involvement Screening Test (ASSIST) is a
questionnaire to screen for levels of risk for alcohol, smoking and
substance use in adults. ASSIST scores were calculated for all par-
ticipants. A risk score for alcohol was calculated as low risk (score
0–3), moderate risk (score 4–26) or high risk (score ≥27) [31].
2.3. Laboratory assessments
Peripheral blood samples were collected from all participants
after 12–14h overnight fasting. Lipid hydroperoxides were mea-
sured by the ferrous oxidation of xylenol assay using an adaptation
of the technique described by Jiang [16]. The levels of nitric oxide
metabolites (NOx)were assessed bymeasuring the plasma concen-
tration of nitrite and nitrate, using an adaptation of the technique
described by Navarro-Gonzálvez et al. [23]. TRAP was measured by
chemiluminescence in an adaptation of the method described by
Repetto et al. [27]. The quantiﬁcation of advancedoxidationprotein
products (AOPP) in plasma used the method described by Witko-
Sarsat et al. [30]. Malondialdehyde (MDA) is a secondary product of
lipid peroxidation andwas determinedusing themethoddescribed
by Jentzch et al. [15].
We measured the serum concentration of hs-CRP by
immunonephelometry system on a BNII analyzer (Siemens®
System BNTMII, Deerﬁeld, IL, USA). ESR was performed by an
automatic analyzer for erythrocyte sedimentation rate determi-
nation (MicroTest1X – Sire Analytical Systems, Udine, Italy). The
quantitative determination of ﬁbrinogen in plasma was based on
the Clauss method. This method measures the rate of ﬁbrinogen towas performed by a coagulation analyser (Destiny Plus – Trinity
Biotech GmbH, Lemgo, Germany). The determination of serum
homocysteine was performed on an ARCHITECT i System (Abbot,
Wiesbaden, Germany).
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Table 1
Demographic and clinical characteristics by smoking and depressive disorder.
Characteristics Never-smoker Smoker p-Valuea
Non-depressed (n=123) Depressed (n=68) Non-depressed (n=78) Depressed (n=72)
n % n % n % n %
Gender 0.008
Male 47 (38.2) 14 (20.6)* 35 (44.9) 20 (27.8)
Female 76 (61.8) 54 (79.4)* 43 (55.1) 52 (72.2)
Age 0.079
18–29 6 (4.9) 1 (1.5) 4 (5.1) 6 (8.3)
30–39 18 (14.6) 8 (11.8) 8 (10.3) 12 (16.7)
40–49 63 (51.2) 38 (55.9) 29 (37.2) 25 (34.7)*
50–60 36 (29.2) 21 (30.9) 37 (47.4)** 29 (40.3)
Ethnicity 0.524
Caucasian 84 (68.3) 48 (70.6) 53 (67.9) 48 (66.7)
African 14 (11.4) 5 (7.4) 8 (10.3) 9 (12.5)
Asian 9 (7.3) 3 (4.4) 4 (5.1) 0 (.0)*
Mixed 16 (13.0) 12 (17.6) 13 (16.7) 15 (20.8)
Marital status 0.289
Stable relationship 85 (69.1) 48 (70.6) 52 (66.7) 40 (55.6)
Years of education 0.000
≤12 years 28 (22.8) 9 (13.2) 58 (74.4)** 51 (70.8)**
≥13 years 94 (76.4) 55 (80.9) 19 (24.4)** 18 (25.0)**
Disability for work 0.000
Yes 2 (1.6) 1 (1.5) 14 (17.9)** 19 (26.4)**
Suicide attempt
Yes 0 (.0) 2 (2.9) 2 (2.6) 22 (30.6)** 0.000
Hamilton scale (mean, SD)
Yes 1.6 (2.3) 6.9 (7.9) 4.5 (4.6) 14.4 (9.4)** 0.000
Alcohol ASSIST
Yes 1 (.8) 1 (1.5) 8 (10.3)** 16 (22.2)** 0.000
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.4. Statistical analyses
Analyses were performed examining the relationship between
he non-depressed never-smoker with depressed smokers, non-
epressed smokers and depressed never smokers. Comparisons
ere made between these for socio-demographic, clinical and lab-
ratory measurements, using appropriate parametric tests where
atawere normally distributed andnon-parametric statistical tests
or categorical or non-normal data. All tests were 2-tailed and a
-value of 0.05 was used for statistical signiﬁcance.
Univariate comparisons were initially conducted and then
ariables that were statistically signiﬁcant were included in the
ultivariate analyses. A generalized multinomial regression anal-
siswas carried out using non-depressed never-smoker, depressed
ever-smoker, non-depressed smoker and depressed smoker cat-
gories as the dependent variable. The multinomial regression
nalysis was used to estimate the odds that depressed never-
mokers, non-depressed smokers or depressed smokers, compared
ith non-depressed never-smokers, was associated with each of
he independent variables. All analyses were performed using SPSS
Version 20).
. Results
In examining socio-demographic and clinical variables, smoking
nd depressive status did not differ with respect to marital sta-
us, age and ethnicity. The depressed and non-depressed smokers
ere signiﬁcantly different in having fewer years of education and
ore disability for work compared to non-depressed never smok-
rs (p<0.01). Depressed smokers had signiﬁcantly more disability
or work than non-depressed never smokers (p<0.01). The mean
ge for all groups was 46.25 years (Table 1).
Depressed smokers showed statistically signiﬁcant differ-
nces in consuming more alcohol, requiring more frequentl–Wallis test, other characteristics it is based on the Pearson Chi-square test.
hospitalization, attempting suicide more frequently, and being
more unable to work than non-depressed never smokers. The
depressed smokers also exhibited signiﬁcant differences in severity
of depression (higher Hamilton scores) compared with depressed
never smokers (Table 1).
Depressed smokers had signiﬁcantly higher levels of oxidative
stress (NOx, AOPP) and lower levels of antioxidants (TRAP), higher
levels of inﬂammatory biomarkers (ﬁbrinogen, hs-CRP, ESR) com-
pared to non-depressed never smokers However, smokers from all
groups did not differ with respect to levels of homocysteine, lipid
hydroperoxides and MDA (Table 2).
These results did not change when we analyzed these vari-
ables using multinomial regression analysis after adjusting for
gender, age, years of education, disability for work, and labora-
tory measures. We found the levels of NOx, AOPP (OR=1.02, 95%
CI =1.01–1.03), and ﬁbrinogen were substantially higher, and lev-
els of TRAP were lower (OR=0.99, 95% CI =0.99–1) in depressed
smokers compared to non-depressed never smokers. However, the
association between hs-CRP and ESR in depressed smokers was
no longer signiﬁcant after the multinomial regression analysis. On
the other hand, we found signiﬁcant differences in levels of lipid
hydroperoxides (OR=3.14, 95% CI =1.25–7.88) (Table 3).
Using multinomial regression analysis, depressed never
smokers comprised more women (odds ratio was 4.06, 95%
CI =1.58–10.43) compared to non-depressed never smokers.
Depressed smokers were more unable to work (OR=7.85, 95%
CI =1.29–47.90) compared to non-depressed never smokers.
4. DiscussionThe current study demonstrated that depressed smokers had
signiﬁcantly higher levels of oxidative stress such as raised
NOx (products of nitrates and nitrites), lipid hydroperoxides (a
biomarker of oxidative damage to lipids), AOPP (a biomarker
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Table 2
Comparison of laboratory measurements of oxidative stress and inﬂammatory biomarkers by smoking status and/or depressive disorder.
Laboratory measures Never-smoker Smoker p-Valuea
Non-depressed Depressed Non-depressed Depressed
Mean SD Mean SD Mean SD Mean SD
CRP 2.8 (4.1) 2.5 (3.4) 4.1 (4.7)** 4.1 (4.7)** 0.000
NOx 3.3 (1.8) 3.3 (2.1) 5.3 (2.7)** 4.5 (2.1)** 0.000
Lipid hydroperoxides 0.9 (.4) 0.9 (.4) 1.0 (.4) 1.1 (.6)* 0.125
AOPP 98.5 (38.6) 103.5 (41.8) 109.9 (46.9)** 117.3 (48.0)** 0.018
TRAP 838.3 (131.7) 830.7 (135.3) 836.0 (142.5) 780.1 (126.8)** 0.020
MDA 16.0 (5.4) 14.8 (5.4) 16.0 (5.4) 16.4 (7.1) 0.501
Fibrinogen 327.9 (66.2) 323.4 (62.1) 368.1 (73.8)** 365.6 (67.9)** 0.000
ERS 12.3 (10.8) 11.5 (9.1) 14.6 (10.5) 17.8 (14.3)* 0.015
a The p-value for all the laboratory measurements except TRAP is based on the independent samples Kruskal–Wallis test and for TRAP it is based on the oneway ANOVA.
d nev
v
o
b
I
b
s
s
n
p
d
s
d
d
d
p
o
o
o
a
t
l
e
l
F
t
s
t
T
M* Signiﬁcance at the 0.05 level.
** Signiﬁcance at the 0.01 level and the comparison is between the non-depresse
ariables except TRAP and for TRAP it is based on the independent sample t-test.
f oxidative damage to proteins) and lower levels of TRAP (a
iomarker of anti-oxidants) than non-depressed never smokers.
n depressed smokers we also found differences in inﬂammatory
iomarkers such as ﬁbrinogen compared to non-depressed never
mokers. Furthermore, non-depressed and depressed smokers had
igniﬁcantly higher levels of NOx and ﬁbrinogen compared to
on-depressed never smokers. Our results were consistent with
revious studies which have examined markers of oxidative stress
isturbances in patients with depression, but which did not con-
ider comorbid nicotine dependence [10,29]. Our study included
epressed smokers with nicotine dependence.
This study provides evidence for an association between
epressed smokers and higher levels of AOPP, a measure of oxi-
ation damage to proteins [1]. AOPP correspond to highly oxidized
roteins and speciﬁcally to albumin and might be formed during
xidative stress by reaction of plasma proteins with chlorinated
xidants. Thus, AOPP have been considered as a novel marker of
xidant-mediated protein damage [1].
Patients with both major depression and nicotine dependence
lso had higher levels of lipid hydroperoxides, a marker of oxida-
ive damage. Consistent with previous research that found higher
evels of serum F2a-isoprostanes (8-iso-PGF2a), we found high lev-
ls of lipid hydroperoxides, a biomarker of oxidative damage to
ipids, in depressed compared to non-depressed individuals [33].
urthermore, depressive smokers had signiﬁcantly lower concen-
rationsofTRAP, ameasureof global antioxidantdefenses. Cigarette
moking and depression are signiﬁcant factors in alterations of
he oxidant and antioxidant balance in blood, resulting in potent
able 3
ultinomial regression analysis of variables associated with smoking and/or depression.
Independent variables Depressed never-smoker versus
non-depressed never-smokers
Non-de
non-de
ORb 95% CI p-Value ORb
Femalea 4.06 (1.58–10.43) 0.00** 0.84
Age 1.02 (0.98–1.07) 0.29 1.02
Years of education 1.03 (0.96–1.12) 0.40 0.78
Disability for work,a yes 0.60 (0.04–8.32) 0.70 5.17
CRP 0.98 (0.88–1.09) 0.72 0.94
NOx 1.03 (0.85–1.25) 0.75 1.45
Lipid hydroperoxides 1.56 (0.65–3.71) 0.32 1.41
AOPP 1.01 (1.00–1.02) 0.15 1.01
TRAP 1.00 (1.00–1.00) 0.56 1.00
Fibrinogen 1.00 (0.99–1.01) 0.63 1.01
ERS 0.96 (0.92–1.01) 0.11 0.96
a Reference categories: gender, male; disability for work, no.
b Odds ratios (OR) mutually adjusted for each of the presented variables.
* p=0.05.
** p=0.01.er-smokers and the other three groups based on the Mann–Whitney U test for all
oxidative stress and in these conditions a lipoperoxidation process
can occur [5,19].
In our study, ﬁbrinogen concentrations were higher in smokers
with and without depression compared to non-depressed never
smokers. These ﬁndings are in accordance with other research
that has found strong associations between ﬁbrinogen, persistent
depressive symptoms and smoking [12]. Fibrinogens and hs-CRP
are inﬂammatory biomarkers. Thus, cigarette smoking and depres-
sive disorders may increase the levels of inﬂammatory biomarkers
and the production of oxidants, and may decrease the levels of
antioxidants. An increase in inﬂammation and oxidative stress is
documented in mood disorders [2,19]. There is also data linking
oxidative stress and inﬂammation in cigarette smoking and lung
disease [28].
Higher levels of CRP were consistently associated with depres-
sive disorder, and remained signiﬁcant after controlling for gender,
age, smoking status, physical activity weight, as well as medication
use and medical conditions potentially inﬂuencing inﬂammation
levels [9,18,25]. Furthermore, in univariate analyses, there were
higher levels of CRP in smokers with and without depression than
non-depressed never smokers. However, in multinomial analysis
our data did not suggest that the highest levels of CRP were a
consequence of smoking or depressive disorder.
Our study found an association between higher levels of NOx
and smokers with and without depression compared with non-
depressed never smokers. Higher concentration of plasma NOx in
patients with recurrent depressive disorder was associated with
the severity of depressive symptom and cognitive impairment,
pressed smoker versus
pressed never-smokers
Depressed smoker versus
non-depressed never-smokers
95% CI p-Value ORb 95% CI p-Value
(0.34–2.08) 0.70 1.48 (0.55–3.98) 0.44
(0.98–1.07) 0.30 0.99 (0.95–1.04) 0.74
(0.72–0.86) 0.00** 0.82 (0.75–0.90) 0.00**
(0.86–30.99) 0.07 7.85 (1.29–47.9) 0.03*
(0.85–1.04) 0.25 0.93 (0.83–1.03) 0.16
(1.21–1.75) 0.00** 1.28 (1.05–1.57) 0.02*
(0.56–3.52) 0.47 3.14 (1.25–7.88) 0.01*
(1.00–1.02) 0.10 1.02 (1.01–1.03) 0.00**
(0.99–1.00) 0.07 0.99 (0.99–1.00) 0.00**
(1.01–1.02) 0.00** 1.01 (1.01–1.02) 0.00**
(0.92–1.00) 0.07 0.97 (0.93–1.01) 0.18
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uggesting that an overproduction of nitric oxide via inducible
itric oxide synthase, inducible nitric oxide synthase (iNOS), which
esults in oxidative stress and cell damage [29]. Increased produc-
ion of NO and peroxynitrite may cause nitration and nitrosylation
f proteins that appears related to the pathogenesis of depression
22]. Induction of nitric oxide leads to an activation of nuclear factor
appa B (NF-B), which is relevant to the development of depres-
ive disorders [26].
Depressive smokers were more unable to work, showed more
evere depressive symptoms and attempted suicide more fre-
uently compared with non-depressed never smokers. Our data
re consistent with previous reports that have shown that current
moking is associated with subsequent suicidal behavior [4] and
ore disability for work and more hospitalization [7,24].
The results of this study should be interpreted with regard to
ts strengths and limitations. The present study design was a cross-
ectional study,which can only examine an exposure at a particular
ime, but cannot determine causal relationships [11]. In our study,
he never smokers were highly educated; this could generally lead
o healthy behavior patterns.
Despite of some limitations, our ﬁndings provide evidence of a
ink between depressed smokers and altered oxidative stress and
nﬂammatory marker. In addition, our data suggest that depressed
mokers were more unable to work, showed more severe depres-
ive symptoms and attempted suicide more frequently.
. Conclusion
Our results corroborate the inﬂammatory, oxidative and
itrosative stress theory of depression, and suggest that inﬂam-
atory, oxidative and nitrosative stress could be worsened by
oncomitant nicotine dependences. Depressed smokers exhibited
ltered concentrations of NOx, lipid hydroperoxides, AOPP, TRAP,
nd ﬁbrinogen. Depressive smokers were more unable to work,
howed more severe depressive symptoms and attempted suicide
ore frequently.
Theseﬁndingsneed further studies tobetter understand the role
f shared inﬂammatory, oxidative and nitrosative stress pathways
n depressive disorders and nicotine dependence, which impacts
n the course and severity of both diseases. The translational
mplications of these ﬁndings include the opportunity to iden-
ify subgroups of major depressive disorder with comorbidity with
icotine dependence, to potentially protect them from the effects
f oxidants by applying new therapies.
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